-
公开(公告)号：US6093725A
公开(公告)日：2000-07-25
申请号：US3115
申请日：1998-01-06
申请人： David Cook , John E. Merritt , Aileen Nerio , Henry Rapoport , Adonis Stassinopoulos , Susan Wollowitz , Jan Matejovic
发明人： David Cook , John E. Merritt , Aileen Nerio , Henry Rapoport , Adonis Stassinopoulos , Susan Wollowitz , Jan Matejovic
IPC分类号： A61L2/00 , A61M1/02 , B01J20/28 , C07D219/10 , C07D405/12 , C07D493/04 , C07F9/64 , A61K31/44 , C07D219/08
CPC分类号： C07D405/12 , A61L2/0082 , A61L2/0088 , A61M1/0209 , B01J20/28 , C07D219/10 , C07D493/04 , C07F9/64
摘要： Compounds and methods for inactivating pathogens in materials are described, including compositions and methods for inactivating pathogens in biological materials such as red blood cell preparations and plasma. The compounds and methods may be used to treat materials intended for in vitro or in vivo use, such as clinical testing or transfusion. The compounds are designed to specifically bind to and react with nucleic acid, and then to degrade to form breakdown products. The degradation reaction is preferably slower than the reaction with nucleic acid.
-
公开(公告)号：US06514987B1
公开(公告)日：2003-02-04
申请号：US09610652
申请日：2000-07-02
申请人： David Cook , John E. Merritt , Aileen Nerio , Henry Rapoport , Adonis Stassinopoulos , Susan Wollowitz , Jan Matejovic , William A. Denny
发明人： David Cook , John E. Merritt , Aileen Nerio , Henry Rapoport , Adonis Stassinopoulos , Susan Wollowitz , Jan Matejovic , William A. Denny
IPC分类号： A61K3144
CPC分类号： C07D405/12 , A61L2/0082 , A61M1/0209 , B01J20/28 , C07D219/10 , C07D493/04 , C07F9/64
摘要： Compounds and methods for inactivating pathogens in materials are described, including compositions and methods for inactivating pathogens in biological materials such as red blood cell preparations and plasma. The compounds and methods may be used to treat materials intended for in vitro or in vivo use, such as clinical testing or transfusion. The compounds are designed to specifically bind to and react with nucleic acid, and then to degrade to form breakdown products. The degradation reaction is preferably slower than the reaction with nucleic acid.
摘要翻译： 描述了用于灭活材料中的病原体的化合物和方法，包括用于灭活生物材料如红细胞制剂和血浆中的病原体的组合物和方法。 化合物和方法可以用于治疗用于体外或体内使用的物质，例如临床试验或输血。 该化合物被设计成与核酸特异性结合并与其反应，然后降解以形成分解产物。 降解反应优选比与核酸的反应更慢。
-
3.发明授权Method for the photoactivation of 4' and 5' primary aminoalkyl psoralens in platelet preparations 失效4'和5'伯氨基烷基补骨脂素在血小板制剂中的光活化方法
公开(公告)号：US6004741A
公开(公告)日：1999-12-21
申请号：US957307
申请日：1997-10-23
CPC分类号： A61L2/0011 , A01N1/0215 , A01N1/0294 , A61K31/37 , A61K41/0066
摘要： Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, 4' and 5' primary aminoalkyl psoralens are photoactivated in platelet preparations to inactivate pathogens.
摘要翻译： 合成补骨脂素化合物，其在补骨脂素的4,4'，5'和8位上具有取代，其允许增强与病原体核酸的结合。 描述了更高的补骨脂素结合水平和较低的致突变性，导致血液制品中病原体的更安全，更有效和可靠的失活。 本发明考虑使用新的补骨脂素的灭活方法，其不损害用于输血的血液制品的功能。 特别地，4'和5'伯氨基烷基补骨脂素在血小板制剂中被光活化以灭活病原体。
-
4.发明授权Method for inactivating pathogens in blood using photoactivation of 4'-primary amino-substituted psoralens 失效使用4'-伯氨基取代的补骨脂素的光活化来灭活血液中的病原体的方法
公开(公告)号：US5593823A
公开(公告)日：1997-01-14
申请号：US337987
申请日：1994-11-14
IPC分类号： A01N1/02 , A61K31/365 , A61K31/37 , A61K41/00 , A61L2/00 , C07D493/04 , C12N7/06
CPC分类号： C07D493/04 , A01N1/0215 , A01N1/0294 , A61K31/365 , A61K31/37 , A61K41/0019 , A61K41/0066 , A61L2/0011
摘要： Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.
摘要翻译： 合成补骨脂素化合物，其在补骨脂素的4,4'，5'和8位上具有取代，其允许增强与病原体核酸的结合。 描述了更高的补骨脂素结合水平和较低的致突变性，导致血液制品中病原体的更安全，更有效和可靠的失活。 本发明考虑使用新的补骨脂素的灭活方法，其不损害用于输血的血液制品的功能。
-
公开(公告)号：US5556993A
公开(公告)日：1996-09-17
申请号：US465495
申请日：1995-06-05
IPC分类号： A01N1/02 , A61K31/365 , A61K31/37 , A61K41/00 , A61L2/00 , C07D493/04 , C07D493/00
CPC分类号： C07D493/04 , A01N1/02 , A01N1/0205 , A61K31/365 , A61K31/37 , A61K41/0019 , A61K41/0066 , A61L2/0011
摘要： Psoralen compounds are synthesized which have substitutions on the 4,4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.
摘要翻译： 合成补骨脂素化合物，其在补骨脂素的4,4'，5'和8位上具有取代，其允许增强与病原体核酸的结合。 描述了更高的补骨脂素结合水平和较低的致突变性，导致血液制品中病原体的更安全，更有效和可靠的失活。 本发明考虑使用新的补骨脂素的灭活方法，其不损害用于输血的血液制品的功能。
-
公开(公告)号：US06194139B1
公开(公告)日：2001-02-27
申请号：US09407814
申请日：1999-09-28
IPC分类号： A01N102
CPC分类号： C07D493/04 , A01N1/0215 , A61K31/365 , A61K31/37 , A61K41/0019 , A61K41/0066 , A61L2/0011
摘要： Psoralen compounds are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.
摘要翻译： 合成补骨脂素化合物，其在补骨脂素的4,4'，5'和8位上具有取代，其允许增强与病原体核酸的结合。 描述了更高的补骨脂素结合水平和较低的致突变性，导致血液制品中病原体的更安全，更有效和可靠的失活。 本发明考虑使用新的补骨脂素的灭活方法，其不损害用于输血的血液制品的功能。
-
7.发明授权5'-(4-amino-2-oxa)butye-4,4', 8-trinethylpsoralen in synthetic medium 失效5' - （4-氨基-2-氧杂）丁基-4,4'，8-三乙基肌醇在合成培养基
公开(公告)号：US5712085A
公开(公告)日：1998-01-27
申请号：US465148
申请日：1995-06-05
IPC分类号： A01N1/02 , A61K31/365 , A61K31/37 , A61K41/00 , A61L2/00 , C07D493/04 , C07D493/00
CPC分类号： C07D493/04 , A01N1/02 , A01N1/0205 , A61K31/365 , A61K31/37 , A61K41/0019 , A61K41/0066 , A61L2/0011
摘要： Psoralen compounds are synthesized which have substitutions on the 4,4',5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. Also disclosed are compositions comprising 4' or 5'-primary amino substituted psoralens in a synthetic media.
摘要翻译： 合成补骨脂素化合物，其在补骨脂素的4,4'，5'和8位上具有取代，其允许增强与病原体核酸的结合。 描述了更高的补骨脂素结合水平和较低的致突变性，导致血液制品中病原体的更安全，更有效和可靠的失活。 本发明考虑使用新的补骨脂素的灭活方法，其不损害用于输血的血液制品的功能。 还公开了在合成培养基中包含4'或5'-主要氨基取代的补骨脂素的组合物。
-
公开(公告)号：US5625079A
公开(公告)日：1997-04-29
申请号：US462377
申请日：1995-06-05
IPC分类号： A01N1/02 , A61K31/365 , A61K31/37 , A61K41/00 , A61L2/00 , C07D493/04 , C07D493/00
CPC分类号： C07D493/04 , A01N1/02 , A01N1/0205 , A61K31/365 , A61K31/37 , A61K41/0019 , A61K41/0066 , A61L2/0011
摘要： Synthesis of 4,8-dialkyl-4'-bromomethyl-5'-methylpsoralen and 4,8-dialkyl-5'-bromomethyl-4'-methylpsoralen compounds useful as intermediates.
摘要翻译： 用作中间体的4,8-二烷基-4'-溴甲基-5'-甲基睾丸激素和4,8-二烷基-5'-溴甲基-4'-甲基脯氨酸化合物的合成。
-
公开(公告)号：US6017691A
公开(公告)日：2000-01-25
申请号：US599284
申请日：1996-02-09
IPC分类号： A01N1/02 , A61K31/365 , A61K31/37 , A61K41/00 , A61L2/00 , C07D493/04 , A01N63/00 , C12N7/06
CPC分类号： C07D493/04 , A01N1/02 , A01N1/0205 , A61K31/365 , A61K31/37 , A61K41/0019 , A61K41/0066 , A61L2/0011
摘要： Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.
摘要翻译： 合成补骨脂素化合物，其在补骨脂素的4,4'，5'和8位上具有取代，其允许增强与病原体核酸的结合。 描述了更高的补骨脂素结合水平和较低的致突变性，导致血液制品中病原体的更安全，更有效和可靠的失活。 本发明考虑使用新的补骨脂素的灭活方法，其不损害用于输血的血液制品的功能。
-
10.发明授权Method of inactivating pathogens in biological fluids using photoactivated 5-primaryamino psoralens 失效使用光活化的5-次氨基补骨脂素灭活生物液体中的病原体的方法
公开(公告)号：US5871900A
公开(公告)日：1999-02-16
申请号：US966774
申请日：1997-11-07
IPC分类号： A01N1/02 , A61K31/365 , A61K31/37 , A61K41/00 , A61L2/00 , C07D493/04 , C12N7/06
CPC分类号： C07D493/04 , A01N1/0215 , A61K31/365 , A61K31/37 , A61K41/0019 , A61K41/0066 , A61L2/0011
摘要： Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention compemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, 5'-primary amino psoralens are photoactivated in order to inactivate pathogens in biological fluids.
摘要翻译： 合成补骨脂素化合物，其在补骨脂素的4,4'，5'和8位上具有取代，其允许增强与病原体核酸的结合。 描述了更高的补骨脂素结合水平和较低的致突变性，导致血液制品中病原体的更安全，更有效和可靠的失活。 本发明使用新的补骨脂素来模拟使用不损害输血血液制品功能的灭活方法。 特别地，为了灭活生物流体中的病原体，光活化5'-伯氨基补骨脂素。
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.033 秒)
